Safety and Diagnostic Value of Brain Biopsy in HIV patients: a Case Series and Meta-Analysis of 1209 Patients
JNNP 87:722-733, Lee, A.M.,et al, 2016
Neurologic Outcomes and Adjunctive Steroids in HIV Patients with Severe Cerebral Toxoplasmosis
Neurol 79:1762-1766, Sonneville, R.,et al, 2012
Evidence-based Guideline: Antiepileptic Drug Selection for People with HIV/AIDS
Neurol 78:139-145, Birbeck,G.L.,et al, 2012
Controlled Trial of High-Concentration Capsaicin Patch for Treatment of Painful HIV Neuropathy
Neurol 70:2305-2313, Simpson,D.M.,et al, 2008
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
NEJM 362:402-415, 456, Cohen,J.A.,et al, 2010
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
NEJM 376:221-234,280, Hauser, S.L.,et al, 2017
Alemtuzumab for Multiples Sclerosis: Who and When to treat?
Lancet 380:1795-1797, 1792, Springer, T. & Kappos, L., 2012
Acyclovir Resistance in Herpes Simplex Encephalitis
Ann Neurol 67:830-833, Schulte,E.C., et al, 2010
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
NEJM 376:209-220,280, Montalban, X.,et al, 2017
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis
NEJM 373:1418-1428, Kappos, L.,et al, 2015
Anesthetic Drugs in Status Epilepticus: Risk or Rescue?
Neurol 82:656-664, Sutter, R.,et al, 2014
Effect of Rituximab in Patients with Leucine-Rich, Glioma-Inactivated 1 Antibody-Associated Encephalopathy
JAMA Neurol 71:896-900, Irani, S.R.,et al, 2014
Interferon beta for Secondary Progressive Multiple Sclerosis: A Systematic Review
JNNP 84:420-426, La Mantia, L.,et al, 2013
Utility of MRI in Spinal Arteriovenous Fistula
Neruol 79:25-30,15, Toossi, S.,et al, 2012
Advances in Treatment of Bacterial Meningitis
Lancet 380:1693-1702,1623, Van de Beek, D.,et al, 2012
Open Biopsy in Patients With Acute Progressive Neurologic Decline and Absence of Mass Lesion
Neurol 75:419-424, Schuette,A.J., et al, 2010
How Beneficial is Surgery for Cervical Radiculopathy and Myelopathy?
BMJ 341:200-202, Fouyas,I.P., et al, 2010
High-Dose Cytarabine Plus High-Dose Methotrexate Versus High-Dose Methotrexate Alone in Patients with Primary CNS Lymphoma: A Randomised Phase 2 Trial
Lancet 374:1512-1520, 1477, Ferreri,A.,et al, 2009
Best Practice Recommendations for the Selection and Management of Patients with Multiple Sclerosis Receiving Natalizumab Therapy
Mutliple Sclerosis 15:S26-S36, Coyle,P.K.,et al, 2009
Assessment: The Use of Natalizumab (Tysabri) for the Treatment of Multiple Sclerosis (An Evidence-Based Review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 71:766-773, Goodin,D.S.,et al., 2008
How Effective Are Disease-Modifying Drugs in Delaying Progression in Relapsing-Onset MS?
Neurol 69:1498-1507, Brown,M.G.,et al, 2007
Epilepsy in Children
Lancet 367:499-524, Guerrini,R., 2006
Tirofiban for Stroke without Large or Medium-Sized Vessel Occlusion
NEJM 388:2025-2095, Zi,W.,et al, 2023
Brexpiprazole for the Treatment of Agitation and Aggression in Alzheimers Disease
JAMA Neurol 80:1272-1273, Ballard,C., 2023
Efficacy and Safety of Selumetinib in Pediatric Patients with Neurofibromatosis Type 1
Neurol 98:e938-e946, Hwang, J.,et al, 2022
Lenvatinib Therapy for Advanced Thyroid Cancer: Real-Life Data on Safety, Efficacy, and Some Rare Side Effects
JENDSO 6:1-7, Hamidi, S.,et al, 2022
In Patients with Melanoma Brain Metastases, is Combination Immune Checkpoint Inhibition a Safe and Effective First-Line Treatment? A Critically Appraised Topic
Neurologist 27:290-297, Gritsch, D.,et al, 2022
Oral Antiplatelet Therapy for Acute Ischemic Stroke
Stroke 53:e453-e454, Minhas, J.S.,et al, 2022
Favorable Outcomes in Endovascular Therapy for Basilar-Artery Occlusion
NEJM 387:1428-1429, Schonewille, W.J.,et al, 2022
Endovascular Therapy Versus Medical Treatment for Symptomatic Intracranial Artery Stenosis
Stroke 52:e53-e54, Wang, T.,et al, 2021
Endovascular Therapy for Stroke Due to Basilar-Artery Occlusion
NEJM 384:1910-1920,1954, Langezaal, L.C.M.,et al, 2021
Safety and Efficacy of Coma Induction Following First-Line Treatment in Status Epilepticus
Neurol 97:e564-e576, DeStefano, P.,et al, 2021
Does My District Need a Mobile Stroke Unit?
NEJM 385:971-981,1043, Lees, K.R., 2021
Direct to Angiography Suite Without Stopping for Computed Tomography Imaging for Patients with Acute Stroke
JAMA Neurol 78:1099-1107, Requena, M.,et al, 2021
Endovascular Therapy for Stroke Due to Basilar Artery Occlusion
Stroke 52:3410-3413, Nguyen, T.N. & Strbian, D., 2021
Thrombectomy and Thrombolysis of Isolated Posterior Cerebral Artery Occlusion
Stroke 51:254-261, Strambo, D.,et al, 2020
Feasibility, Safety, and Outcome of Endovascular Recanalization in Childhood Stroke
JAMA Neurol 77:25-34, Sporns, P.B.,et al, 2020
Thrombolysis for Acute Ischemic Stroke in the Unwitnessed or Extended Therapeutic Time Window
Neurol 94:e1241-e1248, Tsivgoulis, G.,et al, 2020
Therapeutic-Induced Hypertension in Patients with Noncardioembolic Acute Stroke
Neurol 93:e1955-e1963, Bang,O.H.,et al, 2019
Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct
NEJM 378:11-22,81, Nogueira, R.G.,et al, 2018
Nusinersen Versus Sham Control in Later-Onset Spinal Muscular Atrophy
NEJM 378:625-635, Mercuri, E.,et al, 2018
Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging
NEJM 378:708-718, Albers, G.W.,et al, 2018
MRI-Guided Thrombolysis for Stroke with Unknown Time of Onset
NEJM 379:611-622, 682, Thomalla, G.,et al, 2018
Intravenous Thrombolysis in Unwitnessed Stroke Onset: MR WITNESS Trial Results
Ann Neurol 83:980-993, Schwamm, L.H.,et al, 2018
Efficacy and Tolerability of the new antiepileptic drugs II: Treatment-resistant epilepsy
Neurol 91:82-90, Kanner, A.M.,et al, 2018
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
NEJM 379:722-730,789, Tawbi, H.A.,et al, 2018
Tocilizumab Treatment for New Onset Refractory Status Epilepticus
Ann Neurol 84:940-945, Jun, J.,et al, 2018
Endovascular Treatment for Patients with Acute Stroke Who Have a Large Ischemic Core and Large Mismatch Imaging Profile
JAMA Neurol 74:34-40, Rebello, L.C.,et al, 2017
Long-Term Outcomes after Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis
JAMA Neurol 74:459-469,392, Muraro, P.A.,et al, 2017